Introduction
Cardiac transthyretin (ATTR) amyloidosis is an increasingly recognized cause of heart failure among older individuals. 1 It is an inexorably progressive and eventually fatal restrictive cardiomyopathy. The causative amyloid deposits in the heart may be composed of either wild-type (non-mutated) transthyretin (ATTRwt) or variant transthyretin (ATTRv), the latter associated with numerous mutations in the TTR gene.
Until recently, diagnosis of cardiac ATTR amyloidosis required demonstration of amyloid deposits within an endomyocardial biopsy. 2 However, advances in diagnostic imaging techniques, including cardiac magnetic resonance imaging 3, 4 and bone scintigraphy with technetium-labelled DPD, 5, 6 HMDP, 7 and PYP 8 have enabled noninvasive, non-histological diagnosis of cardiac ATTR amyloidosis, resulting in a greater than 30-fold increase in the diagnosis of this condition in our centre during the past decade. The non-biopsy tary ATTR amyloid cardiomyopathy are TTR V122I, present in 3-4% of African Americans, 11 and TTR T60A, present in many populations with a frequency of up to 1% in one North Western Irish study. 12 Numerous other rare TTR variants are also associated with ATTR amyloid cardiomyopathy. 13 The diagnosis is made at different stages of the natural history of the disease, reflecting awareness within families and physicians, imaging and other resources, and heterogeneous presentations, but the course of both ATTRwt 10 and ATTRv cardiac amyloidosis is ultimately that of gradually progressive cardiac failure and death within 10 years. Current management is symptomatic, centred on rhythm control, diuretics, and careful regulation of fluid balance.
Although there are no specific therapies as yet, a number of targeted anti-amyloid agents, designed either to inhibit ATTR amyloid deposition or to clear away existing cardiac amyloid deposits, are now in Phase 2 and 3 clinical trials and are showing great promise. [14] [15] [16] [17] Currently, there is no substantiated staging system for cardiac ATTR amyloidosis. Grogan et al. 18 recently proposed a staging system using N-terminal pro-B-type natriuretic peptide (NT-proBNP) and troponin T (TnT) for ATTRwt amyloidosis, but this has not been validated and has not been applied to ATTRv amyloidosis. Furthermore, this system is confounded by current worldwide use of five generations of troponin assays made by various manufacturers, with different centres favouring different assays. These include newer high-sensitivity troponin T (hs-TnT) assays, which not only differ in sensitivity but also give different numerical results to older assays, and troponin I assays. 19 We recently identified NT-proBNP and estimated glomerular filtration rate (eGFR), along with age, to be independent prognostic factors in cardiac ATTR amyloidosis 20 and sought to investigate and validate a staging system for cardiac ATTR amyloidosis which is applicable to both ATTRwt and ATTRv amyloid cardiomyopathy based on these two simple, universally employed biomarkers.
Methods Patients
A retrospective analysis of 869 patients diagnosed with cardiac ATTR amyloidosis on the basis of the presence of heart failure in conjunction with either endomyocardial biopsy histology confirming ATTR amyloid or previously established non-biopsy diagnostic criteria, 9 who were routinely followed up at the UK National Amyloidosis Centre, was performed to establish the staging system (test cohort). All patients were managed in accordance with the Declaration of Helsinki and provided informed consent for anonymous publication of scientific data.
Biomarkers
N-Terminal pro-B-type natriuretic peptide was measured with an electrochemiluminescence sandwich immunoassay on the Elecsys system 2010 (Roche Diagnostics). Glomerular filtration rate was estimated (eGFR) according to the standard MDRD formula (including the correction for race). High-sensitivity troponin T assay was performed with a second-generation assay after 16 December 2015, and prior to that, with a first-generation TnT assay.
Statistical methods
The mortality endpoint was defined as time to death from baseline for all deceased patients and time to Censor date, 18 May 2017, from baseline among the remainder. Date of baseline was the same as the date of diagnosis in >95% of patients and was within 1 month of diagnosis in nearly all remaining patients, such that median time from diagnosis to baseline was 0 months. Accuracy of occurrence and date of death among deceased patients, and ongoing survival among those who were censored, was ensured on the basis of UK death certificate data from the UK Office of National Statistics.
To define the staging system, optimal cut points for relevant variables were chosen on the basis of a receiver operating characteristic curve and then by the Youden method. For NT-proBNP, the optimal cut was 3806 ng/L, which gave a sensitivity of 56% and specificity of 68%. A cut point of 3000 ng/L gave a sensitivity of 67% and specificity of 57%. The optimal cut point for eGFR was 49 ml/min/1.73 m 2 (sensitivity 78%, specificity 38%) and a cut point of 45 ml/min/1.73 m 2 [eGFR <45 ml/min/1.73 m 2 defines chronic kidney disease (CKD) Stage 3b] gave a sensitivity of 84% and specificity of 32%. Median NT-proBNP in the test cohort was 3000 ng/L, and this cut point along with NT-proBNP of 4000 ng/L were both good discriminators of survival by log-rank tests. Different cut points for eGFR alone (according to established CKD stages) were then tested for their discriminatory value for survival, and both 45 ml/min and 30 ml/ min were discriminatory. Given the Youden method results, models using both NT-proBNP of 3000 ng/L and 4000 ng/L and eGFR 45 ml/min/ 1.73 m 2 were then tested for their discriminatory ability and proportional representation. The eGFR cut point of 45 ml/min/1.73 m 2 when combined with the NT-proBNP cut point of 3000 ng/L enhanced the discriminatory ability of all models of BNP alone (including an NT-proBNP tertile model), eGFR alone (including an eGFR tertile model) while dividing an acceptable proportion of patients into each of the three stages. KaplanMeier plots were used to view survival from baseline in different groups. Cox proportional hazards regression analysis was used to compare the hazard ratios (HRs) for the three stages in the whole cohort and separately for each of the three amyloid subgroups, with age as a covariate.
The results of the age-adjusted models are summarized using estimated HRs with their 95% confidence interval (CI). Harrell's c-statistic was calculated to measure the discriminatory ability of each model. The staging system was validated using a cohort of 318 patients, comprising all patients diagnosed with cardiac ATTR amyloidosis and followed up at Mondor Amyloidosis Network, Henri Mondor Teaching Hospital, Créteil, France.
Two-sided tests were used for all analyses, and P < 0.05 was considered significant. The data were analysed using Stata 
Results
Baseline characteristics of all patients in the test cohort are shown in Table 1 . Seven hundred and thirty-five (85%) patients were male, and median age at baseline was 77 years. As expected, the majority of patients with ATTRwt and non-V122I-associated ATTRv amyloidosis were Caucasian and nearly all of those with V122I-associated ATTR amyloidosis were of African ancestry.
Median follow-up in the whole test cohort using a reversed survival model was 32.2 months (range 0.1-116 months), and median survival from baseline by the Kaplan-Meier analysis was 57 months (95% CI 49.1-60.4 months). Two-hundred and eighty-one patients died during follow-up. Univariable and multivariable analyses of factors associated with death are shown in Supplementary material online, Tables S1 and S2, respectively. By univariable analyses, NT-proBNP >3000 ng/L and eGFR <45 ml/min/1.73 m 2 were each found to be significantly associated with death (log-rank test, P < 0.0001; Figure 1 ). A staging system was then created using biomarker cut-offs of 3000 ng/L for NT-proBNP and 45 ml/min/1.73 m 2 for eGFR. Stage I was defined as NT-proBNP below or equal to the cut-off and eGFR above or equal to the cut-off, Stage III was defined as NT-proBNP above the cut-off and eGFR below the cut-off, and the remainder was classified as Stage II. Figure 3 . Stage I patients had a median survival that was indeterminable, Stage II patients had a median survival of 49.2 months (95% CI lower limit 41.3 months, upper limit indeterminable), and Stage III patients had a median survival of 32.7 months (95% CI 23.4-37.0 months) (P < 0.0001 for Stage I vs. II and P = 0.0003 for Stage II vs. III). After adjusting for age in ATTRwt amyloidosis, compared with Stage I, the HR for death was 2.26 (95% CI 1.51-3.36, P < 0.001) for Stage II and 4.37 (95% CI 2.80-6.83, P < 0.001) for Stage III ( Table 2) . terminal pro-B-type natriuretic peptide (NT-proBNP) < _3000 ng/L vs. >3000 ng/L (log-rank test, P < 0.0001).
Staging of cardiac ATTR amyloidosis at diagnosis using NT-proBNP and eGFR Table 2) . Among the subset of 115 patients with cardiac ATTR amyloidosis associated with variants other than V122I (Subgroup 3), 70 (61%) were classified as Stage I, 36 (31%) were Stage II, and 9 (8%) patients were Stage III. Survival in non-V122I-associated ATTRv amyloidosis by the Kaplan-Meier analysis, stratified by stage is shown in Figure 5 .
Stage I patients had a median survival of 76.7 months (95% CI lower limit 69.0 months, upper limit indeterminable), Stage II patients had a median survival of 54.0 months (95% CI 28.6-74.6), and Stage III patients had a median survival of 24.1 months (95% CI lower limit 6.3 months, upper limit indeterminable) (P < 0.02 for Stage I vs. II and P < 0.03 for Stage II vs. III). After adjusting for age in non-V122I-associated ATTRv amyloidosis, compared with Stage I, the HR for death was 2.28 (95% CI 1.04-4.98, P = 0.039) for Stage II and 4.05 (95% CI 1.54-10.64, P = 0.005) for Stage III patients ( The staging system was applied to the validation cohort of 318 patients with cardiac ATTR amyloidosis; this cohort consisted of 186 patients with ATTRwt amyloidosis, 68 patients with V122I-associated ATTR amyloidosis and 64 patients with 21 other known pathogenic TTR variants resulting in cardiac ATTR amyloidosis, including 16 variants that were not included in the test cohort. The baseline characteristics of the validation cohort are shown in Table 1 . Despite the 'unselected' nature of the validation cohort, formal calibration with the test cohort indicated remarkable consistency across all three disease stages and a calibration coefficient of 0.999. One hundred and fifty (47%) patients were classified as Stage I, 118 (37%) patients were Stage II, and 50 (16%) patients were Stage III. Survival by KaplanMeier analysis stratified by stage is shown in Figure 6 , and the results from Cox proportional hazards regression analysis, adjusting for age, are shown in Table 2 . Stage I patients had a median survival of 69.2 months, Stage II patients had a median survival of 35.0 months, and Stage III patients had a median survival of 20.5 months (P < 0.0001 for Stage I vs. II and P = 0.01 for Stage II vs. III). After adjusting for age, compared with Stage I, the HR for death was 3.36 (95% CI 1.79-6.29, P < 0.001) for Stage II and 6.92 (95% CI 3.45-13.87, P < 0.001) for Stage III patients. The HR for patients with Stage III cardiac ATTR amyloidosis compared with Stage II was 2.06 (95% CI 1.12-3.79, P = 0.020). Harrell's c-statistic was 0.71 ( Table 2) .
Comparison of HRs for death between this and the previously reported staging system which used TnT and NT-proBNP is shown in Table 2 .
Discussion
We present a staging system that is applicable to both ATTRwt and ATTRv cardiac amyloidosis, using two simple and universally measured serum biomarkers, NT-proBNP and eGFR. Patients are diagnosed with cardiac ATTR amyloidosis at different stages in its natural history and this staging system, which is highly informative on prognosis and will be relevant for stratifying the enrolment of patients into forthcoming clinical trials of novel therapies, represents an important advance, particularly, given its simplicity and wide applicability. The staging system discriminates between the 20% patients with cardiac ATTR amyloidosis who have a median survival of approximately 2 years, the 40% who have a median survival of about 4 years, and the 40% who have a median survival of around 6 years. While our data validate the previously proposed staging system in ATTRwt amyloidosis, using TnT and NT-proBNP measurement, this cardiac biomarker-based system in our own large data set was less discriminatory and less consistent with respect to HRs of death across different genotypes than our NT-proBNP and eGFR system, the performance of which was remarkably similar across all pathogenic TTR genotypes and between the test and validation cohorts ( Table 2) . This, coupled with the widespread availability and consistent inter-assay performance of both the eGFR and NT-proBNP biomarkers used in our staging system, leads us to recommend widespread adoption of this staging system in patients with cardiac ATTR amyloidosis.
Interestingly, a smaller proportion of patients with non-V122I-associated hereditary cardiac ATTR amyloidosis had Stage III disease at the time of diagnosis compared with other types of cardiac ATTR amyloidosis studied here. This is perhaps not surprising since patients with most other pathogenic TTR variants usually have additional autonomic and peripheral nerve amyloidosis, i.e. familial amyloid polyneuropathy, 21 along with a family history of a similar disease phenotype in a 1st-degree relative, such that they may conceivably seek medical attention with earlier cardiac involvement than patients with ATTRwt amyloidosis or V122I-associated cardiac ATTR amyloidosis who are usually diagnosed after developing overt cardiac symptoms. 22 Nonetheless, with the notable exception of V30M-associated ATTR amyloidosis that frequently presents with isolated neuropathic symptoms in the absence of cardiomyopathy (hence exclusion of such patients from this study), by the time patients with non-V122I hereditary ATTR amyloidosis are diagnosed, there is invariably evidence of the characteristic amyloid cardiomyopathy and heart failure on investigation using biomarkers, imaging, and histology. It is also noteworthy that despite there being a similar proportion of patients with V122I-associated cardiac ATTR amyloidosis and ATTRwt cardiac amyloidosis classified with Stage I, Stage II, and Stage III disease, the prognosis of ATTR V122I cardiac amyloidosis was slightly poorer in all three stages. In looking for a possible explanation of this, we noted that eGFR values within each disease stage were similar between patients with V122I and ATTRwt amyloidosis, but median NT-proBNP concentration was higher in Stage II and Stage III patients with V122I (median 5176 ng/L and 9527 ng/L, respectively) compared with wild-type cases (4212 ng/L and 7776 ng/L, respectively). This suggests that the V122I patients may have had slightly more advanced disease at baseline, which is supported further by a higher proportion of this group having New York Heart Association (NYHA) Class III/IV heart failure at baseline (Table 1) . However, poorer survival of patients with V122I-associated ATTR amyloidosis might also reflect a more aggressive disease phenotype or poorer efficacy of supportive heart failure treatment in black individuals. Further studies to determine which of these factors is responsible for the prognostic differences highlighted here will be greatly enhanced by the use of this staging system.
Although there is a correlation between NT-proBNP concentration and eGFR in the general population, the NT-proBNP concentrations that were observed in this patient group and, more importantly, the cut-off of 3000 ng/L is higher than that expected in patients with end-stage renal disease who are euvolaemic and free of significant cardiac disease. The relationship between these two biomarkers in patients with cardiac ATTR amyloidosis, a cause of Type 2 cardiorenal syndrome, is complex and reflects a combination of factors including degree of cardiac infiltration, fluid status, hormonal axes, diuretic requirements, and renal perfusion potentially influenced by renovascular amyloid, thus justifying their combined use within the same model. Until recently, there was no therapy known to alter the natural history of cardiac ATTR amyloidosis. However, several promising treatments have lately emerged for neuropathic ATTR amyloidosis, including antisense oligonucleotide and siRNA therapies, which inhibit TTR production by 80-90% and appear to substantially diminish disease progression. 14, 23 These therapies are currently in Phase 3 clinical trials in patients with hereditary, predominantly neuropathic ATTR amyloidosis and will require evaluation in cardiac ATTR amyloidosis. Although a study of revusiran, the first of these agents to be tested in cardiac ATTR amyloidosis, was discontinued prematurely due to a mortality imbalance, further studies of TTRlowering therapy in cardiac ATTR amyloidosis are likely to follow. Similarly, diflunisal and tafamidis, small molecule drugs that stabilize the circulating TTR tetramer, have shown clinical benefit in neuropathic ATTR amyloidosis, 24, 25 and tafamidis is currently undergoing evaluation in a Phase 3 study in patients with cardiac ATTR amyloidosis. Finally, a novel antibody therapy, which has been shown to clear hepatic and renal amyloid deposits, 16 is undergoing evaluation in patients with cardiac ATTR amyloidosis. The existence of a validated staging system for ATTR amyloid cardiomyopathy, applicable to patients with both ATTRwt and ATTRv amyloidosis, analogous to the 'Mayo' disease staging system that has very successfully been employed to stratify patients with systemic light chain (AL) amyloidosis, 26 will undoubtedly facilitate the clinical development of these promising novel therapies. In summary, we present here a simple, novel staging system for cardiac ATTR amyloidosis, based on two universally measured biomarkers, which stratifies patients with both ATTRwt and ATTRv amyloid cardiomyopathy into prognostic categories. This staging system represents an important advance in the management of cardiac ATTR amyloidosis.
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